Developing a new treatment paradigm for chronic inflammatory diseases. Lead program in cystic fibrosis (CF), currently in Phase 2.
Laurent Pharmaceuticals is a Montréal-based clinical stage company focusing on rare inflammatory diseases. Laurent’s lead candidate, LAU-7b, is a Phase 2 ready oral pro-resolving therapy, a new class of drugs specifically designed to trigger the resolution phase of inflammation. LAU-7b has US-FDA orphan drug designation and is in advanced preparation of a large Phase 2 enroling 136 adult patients with cystic fibrosis in US and Canada.